BiotechTube
PhotoPharmics

PhotoPharmics

Salt Lake City, United States· Est.
photopharmics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

PhotoPharmics is pioneering a novel, non-invasive phototherapy platform for neurodegenerative diseases, with an initial focus on Parkinson's disease. Its lead device, Celeste®, has shown promising improvements in motor and non-motor symptoms in a Phase 2 trial and is now being evaluated in a fully enrolled, FDA-aligned Phase 3 pivotal trial. The company is positioning its at-home therapy as a potential breakthrough adjunctive treatment that could become a new standard of care, with future ambitions to expand the platform to Alzheimer's and other neurodegenerative conditions.

Parkinson's DiseaseNeurodegenerative Diseases

Technology Platform

Non-invasive, at-home photo-neuromodulation device (Celeste®) that delivers specific light wavelengths through the eyes to modulate neural circuits and address symptoms of neurodegenerative diseases.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The massive and growing Parkinson's disease patient population represents a multi-billion dollar market with decades of unmet need for treatments that address both motor and non-motor symptoms.
Successful approval could establish a first-in-class neuromodulation platform with potential expansion into other neurodegenerative diseases like Alzheimer's.
The at-home, non-invasive nature of the therapy aligns perfectly with trends toward decentralized, patient-centric care.

Risk Factors

The company faces high clinical risk, as its entire value depends on the success of a single Phase 3 pivotal trial.
Regulatory approval for a novel device is uncertain, and commercial success would require convincing adoption by neurologists and securing insurance reimbursement.
As a one-asset, pre-revenue company, it is highly vulnerable to clinical, regulatory, or financing setbacks.

Competitive Landscape

PhotoPharmics competes in the broad Parkinson's disease treatment market, dominated by drug therapies (Levodopa, dopamine agonists, MAO-B inhibitors) and invasive surgical options like Deep Brain Stimulation (DBS). Its primary competition comes from other non-invasive neuromodulation devices in development and digital therapeutics. Its key differentiator is the specific photo-neuromodulation mechanism and its focus on a wide range of symptoms.

More companies in Neuroscience & CNS →More companies in United States →